Arena Investors: You Need More Than a Blockbuster

Reaching $1 billion in annual sales won't cut it for Arena investors

Brenton Flynn
Brenton Flynn
Feb 12, 2013 at 2:45PM
Health Care

Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) are the epitome of water-cooler stocks. Every American knows that our country is dealing with an obesity epidemic, so what could be more of a "sure thing" stock than companies behind weight management pills that are clinically proven to work? If it sounds to good to be true, it's because it is.

In the following video, health care bureau chief Brenton Flynn provides a brief overview for those who are new to the Arena Pharmaceuticals story. Specifically, he discusses why a partnership that Arena entered into means that its drug, Belviq, needs to become much more than a blockbuster drug to provide shareholders with the profits they're looking for.